Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atrophy of Vagina Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy

NCT01502527
View directory record Official record
Conditions
Vulvo Vaginal Atrophy
Interventions
Femarelle
Dietary Supplement
Lead sponsor
Dr. Lila Nachtigall Rapid Medical Research, New York
Other
Eligibility
40 Years to 85 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 2 Interventional

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

NCT02150525
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
Interventions
omega-3 fatty acid, placebo, Questionnaire administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Randomized, Controlled Trial With Hybrid Fractional Laser

NCT03647189
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 9, 2026, 3:16 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis

NCT00816556
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Estriol, Estradiol valerate, Vanicream Lite
Drug
Lead sponsor
Maire Mac Bride
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

NCT04079218
View directory record Official record
Conditions
HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis
Interventions
Estradiol Vaginal Insert
Drug
Lead sponsor
Kerry Murphy
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

NCT01358760
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

DHEA Against Vaginal Atrophy - Safety Study of 12 Months

NCT01256671
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
31
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

NCT00361569
View directory record Official record
Conditions
Menopause
Interventions
DR-2041a, DR-2041b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 4 Interventional

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

NCT07346287
View directory record Official record
Conditions
Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
Interventions
7-940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

NCT01779947
View directory record Official record
Conditions
Atrophic Vaginitis Due to Menopause
Interventions
Estradiol Vaginal Tablets 10 mcg, placebo
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
25
States / cities
Huntsville, Alabama • Montgomery, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

NCT01455597
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
64
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 9, 2026, 3:16 PM EDT
Terminated Phase 2 Interventional Results available

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

NCT04493333
View directory record Official record
Conditions
Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions
Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer
Drug · Combination Product
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

NCT02195986
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

NCT02668796
View directory record Official record
Conditions
Vulvar and Vaginal Atrophy
Interventions
Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk), Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Mahwah, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

NCT02770365
View directory record Official record
Conditions
Atrophy
Interventions
estrace cream (Perrigo), estrace cream (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 9, 2026, 3:16 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of the NuEra Tight VRF for the Treatment of Vaginal and Vulvar Tissue Laxity

NCT04511260
View directory record Official record
Conditions
Vagina Atrophy
Interventions
NuEra Tight VRF Handpiece
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 9, 2026, 3:16 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Vaginal Estradiol Use in Pessary Care

NCT05458375
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina, Vaginal Atrophy
Interventions
Estradiol vaginal cream
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy

NCT05398172
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
MorpheusV Applicator
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Newport Beach, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Early Phase 1 Interventional Results available

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

NCT01697345
View directory record Official record
Conditions
Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions
Testosterone
Drug
Lead sponsor
Creighton University
Other
Eligibility
50 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

NCT00803335
View directory record Official record
Conditions
Pelvic Organ Prolapse, Vaginal Atrophy
Interventions
Vaginal conjugated estrogen cream 0.5gm, Vaginal conjugated estrogen cream 1.0gm
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 9, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 9, 2026, 3:16 PM EDT